Roche (United Kingdom)

Recent papers from Roche (United Kingdom)

1. CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation studyBlood Advances · 2026
2. Beyond measurement: a strategic perspective on antibody–drug conjugates bioanalysis from the European Bioanalysis ForumBioanalysis · 2026
3. Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial ResultsNeurology and Therapy · 2026
4. Neuromelanin‐Sensitive MRI as a Marker of Clinical Severity and Disease Burden in Parkinson's Disease: A Systematic Review and Meta‐analysisMovement Disorders · 2026
5. Ocrelizumab treatment and disability progression in non-Hispanic Black and Hispanic or Latino individuals with relapsing multiple sclerosis: A post hoc analysis of the OPERA I and II trialsMultiple Sclerosis Journal · 2026
6. Zilebesiran in combination with a diuretic in patients with uncontrolled hypertension: a subgroup analysis from the Phase 2 KARDIA-3 trialEuropean Heart Journal · 2026
7. Defining the clinical benefits of disease-modifying therapy in people living with spinal muscular atrophy who require permanent ventilation: a UK-based modified Delphi consensus processEClinicalMedicine · 2026
8. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialThe Lancet · 2024
9. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet · 2008
10. Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myelomaBlood Advances · 2026
11. Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trialNature Medicine · 2026
12. Qualitative research of Dup15q syndrome symptoms and impacts to inform disease concept modelsOrphanet Journal of Rare Diseases · 2026
13. Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular EdemaOphthalmology and Therapy · 2026
14. Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized TrialsOphthalmology · 2026
15. Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trialThe Lancet Oncology · 2026
16. Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation studyBritish Journal of Haematology · 2026
17. Capacity building in medicines development and regulation in Africa — Overview on recent progressBritish Journal of Clinical Pharmacology · 2026
18. Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancerESMO Open · 2026
19. Obinutuzumab Induces Histological Remission and Deep Kidney Parenchymal B-Cell Depletion in Patients with Lupus Nephritis: Exploratory Analyses of the Phase III REGENCY TrialThe Journal of Rheumatology · 2026
20. Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patientsInternational Journal of Lung Cancer · 2026